Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report

被引:0
作者
Lin, Yufu [1 ,2 ]
Chen, Yabo [3 ]
Lin, Shenggan [2 ,4 ]
Zheng, Jingmei [5 ]
Zhang, Xiuping [1 ,2 ,6 ]
Gan, Lu [1 ,2 ,6 ]
机构
[1] Fudan Univ, Zhongshan Hosp Xiamen, Dept Oncol, Xiamen, Peoples R China
[2] Xiamen Clin Res Ctr Canc Therapy, Xiamen, Peoples R China
[3] Fudan Univ, Zhongshan Hosp Xiamen, Dept Gen Practice, Xiamen, Peoples R China
[4] Fudan Univ, Zhongshan Hosp Xiamen, Dept Intervent Radiol, Xiamen, Peoples R China
[5] Fudan Univ, Zhongshan Hosp Xiamen, Dept Pathol, Xiamen, Peoples R China
[6] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai 361015, Peoples R China
关键词
gastric cancer; neoadjuvant therapy; gastric artery chemoembolization; tumor microenvironment; programmed cell death-1 (PD-1); pathologic complete response; case report; GASTROESOPHAGEAL JUNCTION; HEPATOCELLULAR-CARCINOMA; OPEN-LABEL; CHEMOTHERAPY; ADENOCARCINOMA; SURGERY; GASTRECTOMY; CARDIA;
D O I
10.1097/CJI.0000000000000488
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cancer is the most common type of gastrointestinal cancer in China which about 80% of patients are locally advanced or advanced when diagnosed. Surgery along brings high recurrence rate for locally advanced gastric cancer (LAGC), and neoadjuvant therapies are needed. The use of programmed cell death-1 (PD-1)/programmed death-ligand 1 inhibitor nowadays improved the disease-free survival for LAGC, however, only <35% of patients achieved pathologic complete response (pCR) after neoadjuvant therapy nowadays. Therefore, new regimens are needed to be investigated. Gastric artery chemoembolization is applied to metastasis gastric cancer and researches showed interventional therapy can enhance the antitumor effect of PD-1 inhibitor. Here, for the first time, we combined gastric artery chemoembolization with tislelizumab (a PD-1 inhibitor) for neoadjuvant therapy of a patient with LAGC. The patient achieved pCR after a D2 resection and tumor regression grade score was 1. After surgery, the patient received tislelizumab 200 mg per 3 weeks, and showed no sign of recurrence after 6 months of follow-up. The study indicated the use of tislelizumab and gastric artery chemoembolization for neoadjuvant therapy may bring a better pCR rate and prognosis of LAGC.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 18 条
[1]  
Al-Batran SE, 2022, J CLIN ONCOL, V40
[2]   Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].
Al-Batran, Salah-Eddin ;
Homann, Nils ;
Pauligk, Claudia ;
Goetze, Thorsten O. ;
Meiler, Johannes ;
Kasper, Stefan ;
Kopp, Hans-Georg ;
Mayer, Frank ;
Haag, Georg Martin ;
Luley, Kim ;
Lindig, Udo ;
Schmiegel, Wolff ;
Pohl, Michael ;
Stoehlmacher, Jan ;
Folprecht, Gunnar ;
Probst, Stephan ;
Prasnikar, Nicole ;
Fischbach, Wolfgang ;
Mahlberg, Rolf ;
Trojan, Joerg ;
Koenigsmann, Michael ;
Martens, Uwe M. ;
Thuss-Patience, Peter ;
Egger, Matthias ;
Block, Andreas ;
Heinemann, Volker ;
Illerhaus, Gerald ;
Moehler, Markus ;
Schenk, Michael ;
Kullmann, Frank ;
Behringer, Dirk M. ;
Heike, Michael ;
Pink, Daniel ;
Teschendorf, Christian ;
Loehr, Carmen ;
Bernhard, Helga ;
Schuch, Gunter ;
Rethwisch, Volker ;
von Weikersthal, Ludwig Fischer ;
Hartmann, Joerg T. ;
Kneba, Michael ;
Daum, Severin ;
Schulmann, Karsten ;
Weniger, Joerg ;
Belle, Sebastian ;
Gaiser, Timo ;
Oduncu, Fuat S. ;
Guentner, Martina ;
Hozaeel, Wael ;
Reichart, Alexander .
LANCET, 2019, 393 (10184) :1948-1957
[3]   Unmasking of α-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolization [J].
Ayaru, Lakshmana ;
Pereira, Stephen P. ;
Alisa, Akeel ;
Pathan, Ansar A. ;
Williams, Roger ;
Davidson, Brian ;
Burroughs, Andrew K. ;
Meyer, Tim ;
Behboudi, Shahriar .
JOURNAL OF IMMUNOLOGY, 2007, 178 (03) :1914-1922
[4]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[5]   Angiogenesis enhanced by treatment damage to hepatocellular carcinoma through the release of GDF15 [J].
Dong, Gang ;
Zheng, Qiong-Dan ;
Ma, Min ;
Wu, Si-Fan ;
Zhang, Rui ;
Yao, Rong-Rong ;
Dong, Yin-Ying ;
Ma, Hui ;
Gao, Dong-Mei ;
Ye, Sheng-Long ;
Cui, Jie-Feng ;
Ren, Zheng-Gang ;
Chen, Rong-Xin .
CANCER MEDICINE, 2018, 7 (03) :820-830
[6]   First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J].
Janjigian, Yelena Y. ;
Shitara, Kohei ;
Moehler, Markus ;
Garrido, Marcelo ;
Salman, Pamela ;
Shen, Lin ;
Wyrwicz, Lucjan ;
Yamaguchi, Kensei ;
Skoczylas, Tomasz ;
Bragagnoli, Arinilda Campos ;
Liu, Tianshu ;
Schenker, Michael ;
Yanez, Patricio ;
Tehfe, Mustapha ;
Kowalyszyn, Ruben ;
Karamouzis, Michalis V. ;
Bruges, Ricardo ;
Zander, Thomas ;
Pazo-Cid, Roberto ;
Hitre, Erika ;
Feeney, Kynan ;
Cleary, James M. ;
Poulart, Valerie ;
Cullen, Dana ;
Lei, Ming ;
Xiao, Hong ;
Kondo, Kaoru ;
Li, Mingshun ;
Ajani, Jaffer A. .
LANCET, 2021, 398 (10294) :27-40
[7]   PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer [J].
Kang, Yoon-Koo ;
Yook, Jeong Hwan ;
Park, Young-Kyu ;
Lee, Jong Seok ;
Kim, Young-Woo ;
Kim, Jin Young ;
Ryu, Min-Hee ;
Rha, Sun Young ;
Chung, Ik Joo ;
Kim, In-Ho ;
Oh, Sang Cheul ;
Park, Young Soo ;
Son, Taeil ;
Jung, Mi Ran ;
Heo, Mi Hwa ;
Kim, Hark Kyun ;
Park, ChoHyun ;
Yoo, Chang Hak ;
Choi, Jin-Hyuk ;
Zang, Dae Young ;
Jang, You Jin ;
Sul, Ji Young ;
Kim, Jong Gwang ;
Kim, Beom Su ;
Beom, Seung-Hoon ;
Cho, Sang Hee ;
Ryu, Seung Wan ;
Kook, Myeong-Cherl ;
Ryoo, Baek-Yeol ;
Kim, Hyun Ki ;
Yoo, Moon-Won ;
Lee, Nam Su ;
Lee, Sang Ho ;
Kim, Gyunji ;
Lee, YeonJu ;
Lee, Jee Hyun ;
Noh, Sung Hoon .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) :2903-+
[8]   Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial [J].
Kudo, Masatoshi .
LIVER CANCER, 2018, 7 (03) :225-234
[9]   CHEMOTHERAPY AND SURGERY FOR LOCALLY ADVANCED CANCER OF THE CARDIA AND FUNDUS - PHASE-II STUDY WITH METHOTREXATE AND 5-FLUOROURACIL [J].
PLUKKER, JT ;
MULDER, NH ;
SLEIJFER, DT ;
GROND, J ;
VERSCHUEREN, RCJ .
BRITISH JOURNAL OF SURGERY, 1991, 78 (08) :955-958
[10]   Embolization of liver tumors: Past, present and future [J].
Rammohan, Ashwin ;
Sathyanesan, Jeswanth ;
Ramaswami, Sukumar ;
Lakshmanan, Anand ;
Senthil-Kumar, Perumal ;
Srinivasan, Ulagendra Perumal ;
Ramasamy, Ravi ;
Ravichandran, Palaniappan .
WORLD JOURNAL OF RADIOLOGY, 2012, 4 (09) :405-412